AVITA Medical, Inc. (RCEL) Key Metrics
RCEL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $403.3M
- Enterprise value
- $375.4M
- P/E (TTM)
- —
- Forward P/E
- 10.3
- PEG ratio
- —
- Price / sales
- 5.3 10-yr median 5.2
- Price / book
- 11.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.99
RCEL key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRCEL valuation Price multiples at each fiscal year-end price.
RCEL returns How much profit the business earns on the capital it uses.
RCEL per-share figures Results divided by the shares outstanding at year-end.
RCEL financial health Debt, liquidity and how easily interest is covered.
RCEL efficiency & capital use Working capital cycle and where the cash goes.
RCEL valuation history
RCEL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RCEL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RCEL price vs earnings per share
RCEL key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $96.1M | $331.3M | $347.5M |
| Enterprise value | $124.0M | $341.4M | $300.9M |
| Price / sales | 1.3 | 5.2 | 6.9 |
| Price / book | — | 73.6 | 7.1 |
| EV / sales | 1.7 | 5.3 | 6.0 |
| Earnings yield | −50.5% | −18.7% | −10.2% |
| Free cash flow yield | −34.3% | −17.6% | −11.4% |
| Share price at fiscal year-end | $3.45 | $12.80 | $13.72 |
| Per share | |||
| Revenue per share | $2.57 | $2.48 | $1.98 |
| Earnings per share | −$1.74 | −$2.39 | −$1.40 |
| Operating cash flow per share | −$1.12 | −$1.89 | −$1.50 |
| Free cash flow per share | −$1.18 | −$2.25 | −$1.56 |
| Cash per share | $0.65 | $1.39 | $3.52 |
| Book value per share | −$0.60 | $0.17 | $1.94 |
| Tangible book value per share | −$0.80 | −$0.04 | $1.92 |
| Capex per share | $0.06 | $0.36 | $0.06 |
| Debt per share | $1.65 | $1.78 | $1.67 |
| Shares outstanding | 27.9M | 25.9M | 25.3M |
| Change in shares outstanding | +7.6% | +2.2% | — |
| Returns & profitability | |||
| Return on equity (ROE) | — | −231.0% | −72.1% |
| Return on invested capital (ROIC) | −260.4% | −525.8% | — |
| Return on assets (ROA) | −71.4% | −64.6% | −31.7% |
| Return on tangible assets | −95.7% | −83.4% | −31.8% |
| Free cash flow margin | −46.0% | −90.7% | −78.7% |
| Financial health | |||
| Total debt | $46.0M | $46.0M | $42.4M |
| Cash & short-term investments | $18.2M | $35.9M | $89.1M |
| Net debt | $27.9M | $10.1M | −$46.6M |
| Debt / equity | — | 10.22 | 0.86 |
| Debt / assets | 0.82 | 0.58 | 0.38 |
| Current ratio | 0.57 | 2.83 | 7.88 |
| Quick ratio | 0.46 | 2.47 | 7.46 |
| Interest coverage | -8.5 | -10.6 | -37.3 |
| Working capital | −$27.2M | $36.8M | $90.8M |
| Invested capital | $11.2M | $14.6M | $2.4M |
| Tangible asset value | −$22.3M | −$1.1M | $48.6M |
| Net current asset value | −$37.6M | −$18.2M | $41.4M |
| Graham net-net per share | −$1.60 | −$1.03 | $1.39 |
| Capital allocation | |||
| Capex / revenue | 2.4% | 14.5% | 2.9% |
| Capex / depreciation | 0.74 | 8.29 | 2.29 |
| Stock-based compensation / revenue | 13.3% | 21.0% | 16.7% |
| R&D / revenue | 29.1% | 31.7% | 41.5% |
| SG&A / revenue | 112.4% | 142.2% | 130.9% |
| Efficiency | |||
| Days sales outstanding | 53.7 | 56.5 | 57.7 |
| Days of inventory on hand | 202.5 | 258.2 | 262.5 |
| Days payables outstanding | 217.6 | 202.4 | 177.9 |
| Cash conversion cycle (days) | 38.6 | 112.2 | 142.2 |
| Receivables turnover | 6.80 | 6.46 | 6.33 |
| Payables turnover | 1.68 | 1.80 | 2.05 |
| Inventory turnover | 1.80 | 1.41 | 1.39 |
| Asset turnover | 1.05 | 0.67 | 0.45 |
| Average receivables | $10.5M | $9.9M | $7.9M |
| Average payables | $7.6M | $5.0M | $3.8M |
| Average inventory | $7.1M | $6.4M | $5.6M |
| Intangibles / total assets | 10.0% | 7.0% | 0.4% |
Computed from RCEL's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RCEL valuation and financial ratios
AVITA Medical earned a return on invested capital of −260.4% in fiscal 2025. It ended the year with $46.0 million of debt and $18.2 million in cash and short-term investments, net debt of $27.9 million.
See the RCEL income statement, the RCEL chart for price history, or the RCEL stock overview for the latest quote and news.
RCEL key metrics FAQ
What is AVITA Medical's ROIC?
AVITA Medical's return on invested capital was −260.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does AVITA Medical have?
AVITA Medical had total debt of $46.0 million at the end of fiscal 2025.
What is AVITA Medical's free cash flow yield?
AVITA Medical generated -$32.9 million of free cash flow in fiscal 2025, a free cash flow yield of −34.3% on its market value at year-end ($96.1 million).
What is AVITA Medical's current ratio?
AVITA Medical's current ratio was 0.57 at the end of fiscal 2025: current assets were 0.57 times current liabilities.